Unique IGHVIII-38-1: A Glycoprotein with Potential as A Drug Target

Target Name: IGHVIII-38-1

NCBI ID: G28346

IGHVIII-38-1

Other Name(s): 38-1 | immunoglobulin heavy variable (III)-38-1 (pseudogene) | 3-38.1P | Immunoglobulin heavy variable (III)-38-1 (pseudogene) | IGHVIII381

Unique IGHVIII-38-1: A Glycoprotein with Potential as A Drug Target

IGHVIII-38-1 (38-1) is a glycoprotein that is expressed in various tissues of the body, including the liver, spleen, and kidneys. It is a member of the IGHVIII family, which consists of five structurally similar proteins (1-5) that share a conserved N-terminus and a characteristic glycosylation pattern. IGHVIII-38-1 is unique among the IGHVIII family due to its unique sequence, which has been implicated in its unique function and potential as a drug target.

The IGHVIII family plays a critical role in the immune response. These proteins are involved in the formation of immune complexes, which are the primary targets of an adaptive T-cell response. They are also involved in regulating the activity of T-cells, which are critical for immune surveillance of the body against infection and disease.

One of the unique features of IGHVIII-38-1 is its unique sequence. Unlike the other members of the IGHVIII family, IGHVIII-38-1 has a unique N-terminus that is distinct from that of its neighbors. This N-terminus is rich in conserved acidic and basic residues, which are important for protein-protein interactions and other cellular processes. The unique N-terminus of IGHVIII-38-1 has been implicated in its unique function and potential as a drug target.

IGHVIII-38-1 has also been shown to play a critical role in the regulation of inflammation. In response to infection or injury, IGHVIII-38-1 is expressed at higher levels in various tissues of the body, including the liver, spleen, and kidneys. It is involved in the formation of immune complexes, which are the primary targets of an adaptive T-cell response. IGHVIII-38-1 is also involved in regulating the activity of T-cells, which are critical for immune surveillance of the body against infection and disease.

In addition to its role in the immune response, IGHVIII-38-1 has also been shown to play a critical role in the regulation of inflammation. In response to infection or injury, IGHVIII-38-1 is expressed at higher levels in various tissues of the body, including the liver, spleen, and kidneys. It is involved in the formation of immune complexes, which are the primary targets of an adaptive T-cell response. IGHVIII-38-1 is also involved in regulating the activity of T-cells, which are critical for immune surveillance of the body against infection and disease.

One of the potential benefits of targeting IGHVIII-38-1 as a drug target is its unique expression pattern in different tissues of the body. Unlike other members of the IGHVIII family, IGHVIII-38-1 is not expressed in the brain, testes, or thymus, which are implicated in the immune response. This unique expression pattern may allow for targeting IGHVIII-38-1 selectively in certain tissues, which could reduce the potential for adverse effects in other tissues.

Another potential benefit of targeting IGHVIII-38-1 as a drug target is its unique function in the immune response. IGHVIII-38-1 is involved in the formation of immune complexes, which are the primary targets of an adaptive T-cell response. This function makes IGHVIII-38-1 an attractive target for drugs that are designed to modulate the activity of T-cells. By targeting IGHVIII-38-1, drugs could potentially modulate the

Protein Name: Immunoglobulin Heavy Variable (III)-38-1 (pseudogene)

The "IGHVIII-38-1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGHVIII-38-1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets